ClinicalTrials.gg
RecruitingNCT06173232Updated Dec 15, 2023

Assessment of Retinal Fundus Imaging Camera

An observational study in Diabetic Retinopathy and Diabetic Macular Edema, sponsored by Digital Diagnostics, Inc.. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Digital Diagnostics, Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
41st of 70
100 · median 161
Started
2023
with 11 others
Observational
70 of 267
8 open now
Primary completion
2024-03
later than 3 of 53 live
Registered
225th of 267
by date
Lead sponsor
4 of 267
Digital Diagnostics, Inc.

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 41st largest by planned enrollment of the 70 observational ones that give a count, is one of 12 that started in 2023, is one of 70 observational ones, reaches primary completion later than 3 of the 53 other live ones, and was the 225th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy per ETDRS level 35 and higher with or without macular edema.

Read the detailed description

The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy (ETDRS level 35 and higher) with or without macular edema. Study subjects will sign the informed consent form, and data collection will involve being imaged by cameras.

03

Conditions studied

  • Diabetic Retinopathy
  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A minimum of 80 eligible subjects, these subjects will be categorized as ETDRS ≥ 35 with or without DME and subjects with ETDRS 20 or less and no DME

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 22 years of age or older.
  • Documented diagnosis of diabetes mellitus, as per any of the following: Having met the criteria established by the World Health Organization (WHO) and/or the American Diabetes Association (ADA), (HbA1c) ≥ 6.5%, Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L), Oral Glucose Tolerance Test (OGTT) with two-hour plasma glucose (2-hr PG) ≥ 200 mg/dL (11.1 mmol/L), using the equivalent of an oral 75g anhydrous glucose dose dissolved in water, Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)
  • Ability to understand and the willingness to sign a written document.
  • Diagnosis from a retinal specialist of ETDRS level of 35 or higher with or without DME or diagnosis from a retinal specialist of ETDRS level 20 or lower and no DME.
  • Standard Corrected Visual Acuity of at least 20/40 or better in both eyes.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in an interventional eye study (e.g., actively receiving the product for Diabetic Retinopathy (DR) and/or Diabetic Macular Edema (DME)).
  • Has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia, or previous enucleation).
  • Pregnancy
  • Has a known allergy to or for the use of Tropicamide 1% or other mydriatic eye drops.
  • Any condition that is contraindicated for the use of study devices in the opinion of the investigator.
  • Contraindication for imaging by devices used in the study due to any of the following:
  • Subject is hypersensitive to light
  • Subject recently underwent photodynamic therapy (PDT)
  • Subject is taking medication that causes photosensitivity
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    Subjects with ETDRS ≥ 35 with or without DME

    Device: Camera Imaging

  • Group 2

    Subjects with ETDRS 20 or less and no DME

    Device: Camera Imaging

Interventions

  • DeviceCamera Imaging

    Camera Imaging

06

What researchers measure

Primary outcomes

  1. Primary Objective

    Agreement of AI device results (mtmDR(+), mtmDR(-)) obtained from fundus cameras

    Time frame: 1 Day

Other outcomes

  1. Exploratory Objective

    Agreement of AI device probability scores obtained from fundus cameras

    Time frame: 1 Day

  2. Exploratory Endpoint

    Agreement of AI device results (mtmDR(+), mtmDR(-), "Exam Quality Insufficient" obtained from fundus cameras

    Time frame: 1 Day

07

Study locations

1 of 1 sites recruiting
  • Midwest Eye Center
    Cincinnati, Ohio 45202, United States
    Recruiting
    • Savannah Hollingsworth · Contact
    • Christopher Devine, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Mar 2024, 4 months after the start.

Of 90 observational studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 61. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 15, 2023
StartActual
Nov 20, 2023
Primary completionEst.
Mar 2024
CompletionEst.
May 2024
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06173232
Lead sponsor
Digital Diagnostics, Inc.
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Nov 20, 2023
Primary completion
Mar 2024 (estimated)
Completion
May 2024 (estimated)
Last update
Dec 15, 2023

Study contacts

Breanne MacMillan, MS
Contact
macmillan@digitaldiagnostics.com
815-931-1354
Audrey Singh, BS
study director · Digital Diagnostics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion